Application of anti-PD-1 antibody and/or anti-PD-L1 antibody in preparation of medicine for treating Parkinson's disease

A PD-L1, PD-1 technology, applied in the field of medicine, can solve the problem of not using Parkinson's disease

Pending Publication Date: 2020-11-20
生物抗素公司
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Anti-PD-1 / PD-L1 antibodies have been used in cancer treatment, but not Parkinson's disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 The effect of anti-PD-1 / PD-L1 antibody on the α-polynucleoprotein oligomer of Parkinson mouse

[0022] In this example, the method of Luk et al. (Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee V. Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice. Science. 2012 ; 338:949–953.) Induce Parkinson's rats. The procedure is as follows: 15 μg α-synuclein fibrils are injected into the striatum of male C57BL / 6 mice. After 60 days, the above-mentioned male C57BL / 6 mice were divided into groups, 10 mice in each group, and the drugs to be tested were injected intravenously: pembrolizumab, tislelizumab, nivolumab, cimiprizumab, carbo Relilizumab, teriprizumab, sintilizumab, as well as atelizumab, avenrizumab, and devaluzumab, each drug is injected in two doses, specific injections The dosage is shown in Table 1, and the injection is performed every 10 days. In addition, male C57BL / 6 mice injected with P...

Embodiment 2

[0036] Example 2 Preparation of oral emulsion

[0037] The preparation method of the emulsion includes the following steps: the anti-PD-1 antibody and / or the anti-PD-L1 antibody are dissolved in a PBS buffer containing 4% Tween-80 at a ratio of 50 mg: 1 mL as an aqueous phase, as follows: 500mg pembrolizumab was dissolved in 10mL PBS buffer containing 4% Tween-80 as the water phase; olive oil containing 6% lecithin was used as the oil phase; then the water phase and the oil were mixed in equal volumes at 3000 revolutions After shaking for 2 minutes, stir at 30000 rpm for 5 minutes.

Embodiment 3

[0038] Example 3 Clinical experiment

[0039] Clinical evaluation uses the Parkinson’s Disease Comprehensive Assessment Scale (MDS-UPDRS) (refer to https: / / www.movementdisorders.org / MDS / MDS-Rating-Scales / MDS-Unified-Parkinsons-Disease-Rating-Scale-MDS-MDS -MDS-UPDRS.htm). The experiment lasted for 12 months. Patients with Parkinson's disease should be diagnosed by a professional doctor as the inclusion criteria. Patients who were tolerant to levodopa drugs were excluded from this experiment. In this example, before the experiment, the patient appropriately reduced the dose of the Parkinson's disease treatment drug levodopa-like drugs used in the early stage, so that the symptoms were obvious. The anti-PD-1 / PD-L1 antibody drug used in this example is a commercial clinical drug, and the usage and dosage of intravenous injection refer to its usage and dosage in anti-cancer treatment.

[0040] Case 1:

[0041] Female, age: 78, weight: 65 kg, height: 1.60 meters, was diagnosed with P...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of medicines, in particular to an application of an anti-PD-1 antibody and / or an anti-PD-L1 antibody in preparation of a medicine for treating the Parkinson's disease. It is found that the anti-PD-1 antibody and / or the anti-PD-L1 antibody can reduce alpha synuclein aggregation, and the anti-PD-1 / PD-L1 antibodies, namely, pembrolizumab, nivolumab, cemiplimab, toripalimab, sintilimab, camrelizumab, tirelizumab, atezolizumab, durvalumab and avenlimab all can reduce alpha synuclein aggregation. In specific clinical application cases, it is found that through intravenous injection or oral administration of the anti-PD-1 / PD-L1 antibody, the Parkinson's disease can be improved, and development of the disease condition can be effectively prevented.

Description

Technical field [0001] The present invention relates to the technical field of medicine, in particular to the application of anti-PD-1 antibody and / or anti-PD-L1 antibody in the preparation of drugs for treating Parkinson's disease. Background technique [0002] Parkinson's disease is a neurodegenerative disease. It became the second most common neurodegenerative disease after Alzheimer's disease. More than ten million people worldwide are suffering from this disease (Ball N, Teo W, Chandra S and Chapman J. Parkinson's Disease and the Environment. Front Neurol. 2019; 10:218.). Its main symptoms are tremor, slow movement, muscle tension, heavy fatigue, impaired posture and balance, constipation, mask face, hunched back and changes in speaking and writing posture. The cause of the disease is still unclear. It is generally believed that in the midbrain, the abnormal aggregation of alpha synuclein causes dopamine-producing cells to fail to work normally or even die, which leads to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P25/16
CPCA61K39/395A61P25/16A61K2039/507A61K2039/505
Inventor 任宇皓蔡慧芝
Owner 生物抗素公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap